A long-term data readout from the phase 3 IT-MATTERS trial highlighted the potential of leukocyte interleukin injection as a treatment for patients with locally advanced primary squamous cell carcinoma of the head and neck, oral cavity, and soft palate.
Primary and secondary end points from the phase 2 PIONEER trial assessing avapritinib in nonadvanced systemic mastocytosis were met.
Trevor M. Feinstein, MD, discussed the phase 3 DUBLIN-3 trial evaluating docetaxel with or without plinabulin for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer.
Alexander I. Spira, MD, PhD, FACP, highlights several unanswered questions within the KRAS G12C–positive non–small cell lung cancer space.
Angela DeMichele, MD, MSCE, spoke about the I-SPY2 trial, which evaluates patients with early breast cancer who are treated with experimental neoadjuvant systemic therapy regimens.
In an update to the phase 3 CANOPY-A trial, investigators reported that canakinumab did not significantly improve disease-free survival over placebo in patients with completely resected non–small cell lung cancer.
Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.
Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.
A real-world, prospective cohort study identified independent predictors may increase the risk of early mortality in patients with newly diagnosed multiple myeloma.
In a population of patients with cervical intraepithelial neoplasia and stage IA1 cervical cancer, certain local treatments, such as radical excision and ablation, were associated with treatment outcomes and risk of preterm birth.
Results from the phase 1/2 ARROW trial showed robust and durable responses in patients with RET fusion–positive cancer treated with pralsetinib.
Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
Paul G. Richardson, MD, presented data from the phase 3 DETERMINATION study at 2022 ASCO and theorized how these findings could extend to similar regimens in newly diagnosed multiple myeloma.
A partial clinical hold placed on the phase 1/2 TakeAim Lymphoma trial was lifted after a strategy to identify and manage rhabdomyolysis was agreed upon.
Investigators found that patients with non–gain-of-function TP53-mutant right-sided metastatic colorectal cancer and gain-of-function TP53-mutant left-sided tumors had poorer survival vs their counterparts.
P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Alexis A. Thompson, MD, MPH, spoke about the use of betibeglogene autotemcel for patients with β-thalassemia.
Based on results from the phase 3 MOMENTUM trial, the FDA has accepted a new drug application of momelotinib for patients with myelofibrosis.
Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.
Positive trends in screening of patients at high risk of lung cancer may double survival in this malignancy, according to Giorgio V. Scagliotti, MD, PhD, at 2022 WCLC.
Patients with previously untreated diffuse large B-cell lymphoma may benefit from treatment with polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone, for which a supplemental biologics license application was accepted by the FDA.
“...we don’t focus on survivorship enough. It’s important to understand the other factors involved in surviving besides just a treatment.”
Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.
Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.
Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s choice of treatment.
Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanios S. Bekaii-Saab, MD.
Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.
The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.
Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.
Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.
